Share >  
Share
Share on Tumblr

Nicholas Piramal

News »

   latest by relevance
Piramal Q4 PAT seen down 5.9% to Rs 122.1 cr: Sharekhan
Apr 10, 2010 at 14:46 | Source: Moneycontrol.com
Sharekhan has come out with its earning estimates on Pharmaceutical sector for the quarter ended March 2010. According to the research firm, Nicholas Piramal March quarter sales are expected to go up by 13.7% to Rs 967.5 crore on YoY basis.
Piramal Healthcare's revenues up by 14.4% to Rs 32.8 bn
Apr 27, 2009 at 16:38 | Source: press release
Piramal Healthcare's revenues for FY2009 up by 14.4% to Rs. 32.8 billion, EBITDA (excluding FOREX impact) for the year was up by 23.7% at Rs. 6.7 billion and Net Profit (excluding FOREX impact) was up by 23.5% to Rs. 4.4 billion.
Rajesh Rai to judge International Rx Club Awards
Aug 27, 2008 at 15:53
Rajesh Rai, Executive Creative Director of Sorento Healthcare Communications, Mumbais largest specialist healthcare communications company, was selected as a judge on the panel for the 22nd Annual Rx Club Show scheduled in September this year.
Ankur Drugs appoints Jayesh Trivedi
Jul 17, 2008 at 18:09
Ex-Ranbaxian to Head International Operations at Ankur Drugs. Mr. Jayesh Trivedi sees Ankur as a strong and serious player. With India gaining ground as a preferred destination of CRAMS, Ankur Drugs is stepping up operations for its presence in the international arena.
Piramal Life developing drug to tackle Glivec resistance
Jun 17, 2008 at 08:31 | Source: Business Line
A plant extract could hold the key to tackling the resistance seen in some patients against Novartis blood cancer drug Glivec, indicates research being done by Piramal Life Sciences Ltd the research arm of drug-maker Piramal Healthcare, or erstwhile Nicholas Piramal India Ltd.
Is Ranbaxy a trendsetter for global M&A deals in pharma?
Jun 11, 2008 at 12:24 | Source: CNBC-TV18
Positive comments on Ranbaxy- Daiichi Sankyo deal are seen coming from the market experts. The deal is seen as the first generics-proprietary partnership in global pharma.Udayan Mukherjee, CNBC-TV18 explains that Ranbaxy is the largest pharmaceutical company in India and would certainly command a bit of a strategic premium.

Videos »
Is Ranbaxy a trendsetter for global M&A deals in pharma?
Piramal Group: From a molecule to a mountain
Nicholas Piramal to list demerged entity in June
Infy nos in line with mkt expectations: Edelweiss
Good day for mkts; Tech leads the way
more »

Photos »

  /  
News across the web »
Clinical trials continue to decline in India
Chennai: India is seeing a decline in the number of human clinical trials because of time-consuming government approvals and rising allegations of unethical tests further hindering possibilities of ga...
Jan 06, 2012 at 18:23 | Source: Livemint
Esop idea spreads across corporate India - Rediff.com Business
One effect of the globalisation of Indian business has been the rise in the grant by companies to staffers of employee stock options.Information technology and IT-enabled services (IT ITeS) sectors ac...
Dec 20, 2011 at 13:19 | Source: Money Rediff News Report
Alliances are a competitive necessity
In an increasingly global and competitive world, alliances have become a matter of competitive necessity, and in some industries, not having alliances can put you at a significant disadvantage, obser...
Dec 18, 2011 at 21:22 | Source: The Hindu BusinessLine
more »
Interact & exchange stock tips & market info »

kats

Platinum Member

29 Followers

Piramal Holding  

TOTHE PIRAMAL HEALTH CARE SHAREHOLDERS.HE ALSO REWARDED GENEROUSLY WH...

10.03 PM Jan 10th

Related News »
Piramal Healthcare Acquires Decision Resources Group
... Healthcare is part of the Ajay Piramal group of companies. The Group is a diversified business house with interests in healthcare, glass manufacturing and real estate. In 1988, the group acquired Nicholas Laboratories, which was a Sara Lee group ...
May 16, 2012 at 04:54 | Source: dealcurry.com
How JHP Pharmaceuticals Enabled Lean/Six Sigma by Digitizing its Quality Processes
Nicholas Piramal, Faulding/MaynePharma, Novartis, Sara Lee, Lion Nathan, Compumedics, and Anca. Grow left QAD and Australia in 2004 to work for MaynePharma, where she managed a number of business expansion projects in their US operations before relocating ...
May 20, 2012 at 16:02 | Source: Industry Week

Follow moneycontrol.com

Facebook Twitter Google Plus RSS Wap SMS SMS Alert iPad iPhone Blackberry OVI Android Window